Gene Universal Inc.

geneuniversal.com

Gene Universal, located in Delaware USA, is a pioneer in the field of gene synthesis and synthetic biology. As a leading company in genomics research and applied biological technology, and with our strong technical force, unparalleled customized service and fast delivery time, we are aiming to provide more cost-effective service and product to accelerate the global research in drug discovery, biology optimization, food and agriculture, etc. Gene Universal is specialized in the area of genetic engineering, biosystem engineering and synthetic biology. By providing our industrialized and highly intensive gene synthesis platform, we could deliver both normal and complex genes in short promised time. We have also developed sophisticated software programs to design and optimize complex gene libraries and genetic systems, with these bioinformatics tools and our high-efficiency production management systems, we are able to satisfy scientific researchers with high-efficient, low-cost, and large-scale synthetic genes and genome DNA.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

COLLAPSE OF £550M DEAL TO SELL WOODFORD'S BIOTECHS SPARKS FIRE SALE FEARS

FierceBiotech | February 10, 2020

news image

A £550 million ($711 million) deal to find new homes for Neil Woodford’s biotech holdings has collapsed, raising the prospect that stakes in companies including Immunocore will be auctioned off for knock-down prices. Woodford became a go-to source of money for private British biotechs in the years after he left Invesco to set up his own fund. However, the illiquid nature of Woodford’s holdings in such companies became a problem as more and more investors began taking money out ...

Read More

NORTHWEST BIOTHERAPEUTICS ANNOUNCES THE COMPLETION OF FINANCING ON A FAVORABLE TERMS FOR APPROXIMATELY $8 MILLION

Northwest Biotherapeutics | August 12, 2020

news image

Northwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the Company has completed a financing on favorable terms for approximately $8 million. The Company anticipates that this financing will help maintain the Company's momentum, and will provide some prudent protection in the midst of the current global economic uncertainties. The financing also further ...

Read More

PROTEONIC ANNOUNCES LICENSING OF TECHNOLOGY FOR BOOSTING THERAPEUTIC PROTEIN PRODUCTION TO IMMUNOMEDICS

ProteoNic | October 20, 2020

news image

ProteoNic BV, a leading provider of technology and services in the field of production of biologics, today announced it has licensed its premium 2G UNic™ technology for boosting therapeutic protein production to Immunomedics, Inc. (NASDAQ: IMMU), a biopharmaceutical company developing immuno-therapeutics for the treatment of cancer and other diseases. Under the agreement, Immunomedics gains commercial rights for application of ProteoNic's technology platform to the development of speci...

Read More

MEDTECH

BIO-ISAC AND NEW YORK METRO INFRAGARD MEMBERSHIP ALLIANCE ANNOUNCE PARTNERSHIP

NY Metro InfraGard | April 28, 2022

news image

The Bioeconomy Information Sharing and Analysis Center (BIO-ISAC) and New York Metro InfraGard Members Alliance® (NYM-IMA) today announced a partnership to address threats unique to the bioeconomy and enable coordination among stakeholders to facilitate a robust and secure industry. BIO-ISAC is a critical resource for cyber threat detection, prevention, protection, response, recovery and resilience in the bioeconomy. It helps spur the development and evaluation of defensive to...

Read More
news image

COLLAPSE OF £550M DEAL TO SELL WOODFORD'S BIOTECHS SPARKS FIRE SALE FEARS

FierceBiotech | February 10, 2020

A £550 million ($711 million) deal to find new homes for Neil Woodford’s biotech holdings has collapsed, raising the prospect that stakes in companies including Immunocore will be auctioned off for knock-down prices. Woodford became a go-to source of money for private British biotechs in the years after he left Invesco to set up his own fund. However, the illiquid nature of Woodford’s holdings in such companies became a problem as more and more investors began taking money out ...

Read More
news image

NORTHWEST BIOTHERAPEUTICS ANNOUNCES THE COMPLETION OF FINANCING ON A FAVORABLE TERMS FOR APPROXIMATELY $8 MILLION

Northwest Biotherapeutics | August 12, 2020

Northwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the Company has completed a financing on favorable terms for approximately $8 million. The Company anticipates that this financing will help maintain the Company's momentum, and will provide some prudent protection in the midst of the current global economic uncertainties. The financing also further ...

Read More
news image

PROTEONIC ANNOUNCES LICENSING OF TECHNOLOGY FOR BOOSTING THERAPEUTIC PROTEIN PRODUCTION TO IMMUNOMEDICS

ProteoNic | October 20, 2020

ProteoNic BV, a leading provider of technology and services in the field of production of biologics, today announced it has licensed its premium 2G UNic™ technology for boosting therapeutic protein production to Immunomedics, Inc. (NASDAQ: IMMU), a biopharmaceutical company developing immuno-therapeutics for the treatment of cancer and other diseases. Under the agreement, Immunomedics gains commercial rights for application of ProteoNic's technology platform to the development of speci...

Read More
news image

MEDTECH

BIO-ISAC AND NEW YORK METRO INFRAGARD MEMBERSHIP ALLIANCE ANNOUNCE PARTNERSHIP

NY Metro InfraGard | April 28, 2022

The Bioeconomy Information Sharing and Analysis Center (BIO-ISAC) and New York Metro InfraGard Members Alliance® (NYM-IMA) today announced a partnership to address threats unique to the bioeconomy and enable coordination among stakeholders to facilitate a robust and secure industry. BIO-ISAC is a critical resource for cyber threat detection, prevention, protection, response, recovery and resilience in the bioeconomy. It helps spur the development and evaluation of defensive to...

Read More